The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy

BJU International

Volumn 110, Issue 1, 2012, Pages 43-49

  Durand, Xavier ^a,b   Xylinas, Evanguelos ^a,c   Radulescu, Camelia ^c   Haus Cheymol, Rachel ^b   Moutereau, Stephane ^c   Ploussard, Gillaume ^a,c   Forgues, Aurelien ^d   Robert, Grégoire ^d   Vacherot, Francis ^a   Loric, Sylvain ^a,c   Allory, Yves ^a,c   Ruffion, Alain ^e   De La Taille, Alexandre ^a,c  

^a INSERM   (France)

^b University of Paris Descartes   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d HÔPITAL PELLEGRIN   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Biomarker; PCA3; Positive margins; Prostate cancer; Prostatectomy; Tumour volume

Indexed keywords

TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; GENETIC CORRELATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MARKER GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR GENE; TUMOR VOLUME; URINALYSIS;

ADULT; AGED; ANTIGENS, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862302363     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10682.x     Document Type: Article

References (17)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin 2007; 57:43-66
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18:581-92 (Pubitemid 46359643)
3. Loeb S, Gonzalez CM, Rohel KA et al.Pathological characteristics of prostate cancer detedted through prostate specific antigen based screening. J Urol 2006; 175: 902-6 (Pubitemid 43200014)
4. Dong F, Jones JS, Stephenson AJ, Magi-Galluzzi C, Reuther AM, Klein EA. Prostate cancer volume at biopsy predicts clinically significant upgrading. J Urol 2008; 179: 896-900
5. Bussemakers MJG, Van Bokhoven A, Verhaegh GW et al. DD3: a new prostate- specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-9 (Pubitemid 30004960)
6. Hessels D, Klein Gunnewiek JM et al.DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-15
7. Deras IL, Aubin SM, Blase A et al.PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 1587-92
8. Haese A, de la Taille A, van Poppel H et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54:1084-88
9. Nakanishi H, Groskopf J, Fritsche HA et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008; 179: 1804-09
10. Whitman EJ, Groskopf J, Ali A et al.PCA3 score before radical prostatectomy predicts extraprostatic extension and tumor volume. J Urol 2008; 180: 1975-8
11. Hessels D, van Gils MP, van Hooij O et al. Predictive value of PCA3 in urinary sediments in determining clinicopathological characteristics of prostate cancer. Prostate 2010; 70: 70-8
12. Chen ME, Johnston D, Reyes AO, Soto CP, Babaian RJ, Troncoso P. A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 2003; 27: 1291-301 (Pubitemid 37185820)
13. Epstein JI, Chan DW, Sokoll LJ et al.Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998; 160: 2407-11 (Pubitemid 29483051)
14. Badaus L, Isbarn H, Eichelberg C et al.Biochemical reccurence after radical prostatectomy: multiplicative interaction between surgical margin status and pathologiacal stage. J Urol 2010; 184:1341-6
15. Marks LS, Fradet Y, Deras IL et al.PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69: 532-5 (Pubitemid 46428401)
16. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer. Eur Urol 2004; 46:182-6 (Pubitemid 38902733)
17. Hoffman RM, Zeliadt SB. The cautionary tale of PSA testing. Arch Intern Med 2010; 170: 1262-3